Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Results for weight loss treatment combo cagrilintide and semaglutide; positive results for treatment of rare form of ALS, and for sefaxersen in adults with primary IgA nephropathy; gene therapy approved for Sanfilippo syndrome; and Lyrfigtu gains approval for FGFR2+ advanced cholangiocarcinoma.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

First treatment approved for Alexander disease; Hyrnuo and Etcamah are approved for lung cancer and breast cancer, respectively; Pelacarsen misses endpoint in the phase 3 HORIZON trial, and atogepant shows promise from relieving menstrual migraines.

Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In a special episode of the MPR Weekly Dose podcast, Dr William Schaffner — professor of preventive medicine and infectious diseases at Vanderbilt University School of Medicine and former CDC Epidemic Intelligence Service officer — discusses the clinical rollout of mFlusiva, the newly-approved mRNA-based influenza vaccine. Dr Schaffner breaks down how this modern platform differs from traditional egg- and cell-based manufacturing, detailing its mechanism of action as a genetic "blueprint" and analyzing the trial data behind its approval for adults aged 50 and older.

Beyond the science, Dr Schaffner offers actionable guidance for health care providers navigating the realities of modern clinical practice. He addresses practical logistics like coadministering mFlusiva alongside routine fall immunizations, including COVID-19, RSV, and pneumococcal vaccines. He also offers empathetic strategies for overcoming vaccine hesitancy, urging clinicians to look beyond technical lectures and focus on patient reassurance and emotional comfort.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.